Complete T cell antigen, but not MHC I–restricted epitope alone, promotes immune cell cross talk and stem-like CD8 ⁺ TIL infiltration. (A and B) Continuous analysis of the scRNAseq data in Fig. 3; (A) the overall signal strength of each population and signaling pathway; (B) bubble plots indicating the probability of the significant ligand–receptor pairs transferred from DCs to other populations with and without SIY-OVAII cell adjuvant therapy. (C) MC38-bearing mice were treated with Bpmel-OVAI-Ea cell therapy. An antibody against H-2kb/OVAI complex was used to detect DCs in DLN that present OVAI antigen. OVAI-presenting DCs were detected in both the ipsilateral and contralateral DLNs 3 days after Bpmel-OVAI-Ea injection. They were also detected in the contralateral DLNs of Bpmel-OVAI. Ipsilateral DLNs from MC38 tumors without cell adjuvant served as a control. (D–G) Cell adjuvant therapy of Bpmel-OVAI-Ea or Bpmel-OVAI started on day 6 after the MC38 inoculation (day 0), and the analysis started on day 15; (n = 5 per group); (D) flow cytometry analysis of DCs in the MC38-side DLN; (F) flow cytometry analysis of CD8⁺ T cell or CD4⁺ T cells in the MC38-side DLN; (G) flow cytometry analysis of CD8⁺ TILs of MC38. Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparison. All data are representative of three similar experiments.